Top

Trials

Published in:

Open Access 01-12-2022 | Parkinson's Disease | Study protocol

Design of the PERSPECTIVE study: PERsonalized SPEeCh Therapy for actIVE conversation in Parkinson’s disease (randomized controlled trial)

Authors: J. J. L. Maas, N. M. De Vries, B. R. Bloem, J. G. Kalf

Published in: Trials | Issue 1/2022

Abstract

Objective

To evaluate the effectiveness of personalized and home-based speech therapy on quality of life, intelligibility, and social participation for people with Parkinson’s disease (PD) who have a reduced intelligibility of speech.

Background

Speech problems in PD have a profound negative impact on social interaction and quality of life. Evidence for speech therapy in PD is growing, but more work remains needed to explore its full potential. Efficacy exists for highly intensive standardized speech treatment programs, but not all patients can comply with this rather intense intervention, especially the more severely affected ones. Here, we aim to study the effectiveness of personalized and home-based (remote) speech therapy in PD on quality of life and speech. The intervention will be supported by a dedicated speech training app. We expect that this approach will improve speech intelligibility and quality of life in patients irrespective of disease stage.

Methods

We will perform a single blind, randomized controlled trial, comparing 8 weeks of speech therapy to no intervention using a waiting list design. A total of 215 PD patients with problems in intelligibility will be recruited by 12 highly experienced speech therapists. All patients will be measured at baseline and after 8 weeks (primary endpoint). Additionally, the experimental group will be re-assessed one more time, after a wash-out period of 24 weeks. The control group will receive deferred treatment after 8 weeks, but without additional follow-up assessments. Our primary outcome is quality of life (as measured with PDQ-39). Secondary outcomes include speech and voice quality, intelligibility, severity of voice and speech complaints, and caregiver burden.

Results

The inclusion of participants has started on March 1, 2019, and is expected to be finalized on April 1, 2021. We expect to have the first results in January 2022.

Conclusions

We will investigate the effectiveness of speech therapy in PD. Particular strengths of our study include a randomized and single-blinded design, the personalized treatment approach, the inclusion of PD patients irrespective of disease stage or severity of the speech complaint, the long-term follow-up, the adequate power, and the use of a patient-relevant primary endpoint. This will allow us to draw firm conclusions about the effectiveness of personalized and remote speech therapy for PD patients in all disease stages.

Trial registration

ClinicalTrials.govNCT03963388. Registered on May 24, 2019

Miller N, Allcock L, Jones D, Noble E, Hildreth AJ, Burn DJ. Prevalence and pattern of perceived intelligibility changes in Parkinson’s disease. J Neurol Neurosurg Psychiatry. 2007;78(11):1188–90. https://doi.org/10.1136/jnnp.2006.110171.CrossRefPubMedPubMedCentral

Miller N, Noble E, Jones D, Burn D. Life with communication changes in Parkinson’s disease. Age Ageing. 2006;35(3):235–9. https://doi.org/10.1093/ageing/afj053.CrossRefPubMed

Maillet A, Krainik A, Debu B, Tropres I, Lagrange C, Thobois S, et al. Levodopa effects on hand and speech movements in patients with Parkinson’s disease: a FMRI study. PLoS One. 2012;7(10):e46541. https://doi.org/10.1371/journal.pone.0046541.CrossRefPubMedPubMedCentral

Pinto S, Ozsancak C, Tripoliti E, Thobois S, Limousin-Dowsey P, Auzou P. Treatments for dysarthria in Parkinson’s disease. Lancet Neurol. 2004;3(9):547–56. https://doi.org/10.1016/S1474-4422(04)00854-3.CrossRefPubMed

Atkinson-Clement C, Sadat J, Pinto S. Behavioral treatments for speech in Parkinson’s disease: meta-analyses and review of the literature. Neurodegener Dis Manag. 2015;5(3):233–48. https://doi.org/10.2217/nmt.15.16.CrossRefPubMed

Herd CP, Tomlinson CL, Deane KH, Brady MC, Smith CH, Sackley CM, et al. Speech and language therapy versus placebo or no intervention for speech problems in Parkinson’s disease. Cochrane Database Syst Rev. 2012;(8):Cd002812.

Herd CP, Tomlinson CL, Deane KHO, Brady MC, Smith CH, Sackley CM, et al. Comparison of speech and language therapy techniques for speech problems in Parkinson’s disease. Cochrane Database Syst Rev. 2012;8. https://doi.org/10.1002/14651858.CD002814.pub2.

Sackley CM, Smith CH, Rick C, Brady MC, Ives N, Patel R, et al. Lee Silverman voice treatment versus standard NHS speech and language therapy versus control in Parkinson’s disease (PD COMM pilot): study protocol for a randomized controlled trial. Trials. 2014;15(1):213. https://doi.org/10.1186/1745-6215-15-213.CrossRefPubMedPubMedCentral

Ramig LA, Fox CM, Halpern AE, Spielman JL, Freeman K. Randomized clinical trial (RCT) of speech and voice treatment for Parkinson’s disease [abstract]. Stockholm: Movement Disorders; 2014.

10.

Ramig L, Halpern A, Spielman J, Fox C, Freeman K. Speech treatment in Parkinson’s disease: randomized controlled trial (RCT). Mov Disord. 2018;0(0).

11.

Ramig LO, Sapir S, Fox C, Countryman S. Changes in vocal loudness following intensive voice treatment (LSVT(R)) in individuals with Parkinson’s disease: a comparison with untreated patients and normal age-matched controls. Mov Disord. 2001;16(1):79–83. https://doi.org/10.1002/1531-8257(200101)16:1<79::AID-MDS1013>3.0.CO;2-H.

12.

Mahler LA, Ramig LO, Fox C. Evidence-based treatment of voice and speech disorders in Parkinson disease. Curr Opin Otolaryngol Head Neck Surg. 2015;23(3):209–15. https://doi.org/10.1097/MOO.0000000000000151.CrossRefPubMed

13.

de Swart BJM, Willemse SC, Maassen BAM, Horstink MWIM. Improvement of voicing in patients with Parkinson’s disease by speech therapy. Neurology. 2003;60(3):498–500. https://doi.org/10.1212/01.WNL.0000044480.95458.56.CrossRefPubMed

14.

Levitt JS, Chitnis S, Walker-Batson D. The effects of the “SPEAK OUT! (R)” and “LOUD Crowd (R)” voice programs for Parkinson disease. Int J Health Sci. 2015;3(2):13–9.

15.

Wight S, Miller N. Lee Silverman Voice Treatment for people with Parkinson’s: audit of outcomes in a routine clinic. Int J Lang Commun Disord. 2015;50(2):215–25. https://doi.org/10.1111/1460-6984.12132.CrossRefPubMed

16.

Dias AE, Limongi JCP, Barbosa ER, Hsing WT. Voice telerehabilitation in Parkinson’s disease. CODAS. 2016;28(2):176–81. https://doi.org/10.1590/2317-1782/20162015161.CrossRefPubMed

17.

Theodoros DG, Hill AJ, Russell TG. Clinical and quality of life outcomes of speech treatment for Parkinson’s disease delivered to the home via telerehabilitation: a noninferiority randomized controlled trial. Am J Speech Lang Pathol. 2016;25(2):214–32. https://doi.org/10.1044/2015_AJSLP-15-0005.CrossRefPubMed

18.

Ho AK, Iansek R, Bradshaw JL. The effect of a concurrent task on Parkinsonian speech. J Clin Exp Neuropsychol. 2002;24(1):36–47. https://doi.org/10.1076/jcen.24.1.36.972.CrossRefPubMed

19.

Radboudumc. Voice trainer: Radboudumc; 2019 Available from: https://www.radboudumc.nl/afdelingen/revalidatie/voice-trainer.

20.

de Swart BJM, de Wit S, Kalf H. De Pitch Limiting Voice Treatment. Handleiding voor de behandeling hypokinetische dysartrie. Nijmegen: Radboudumc, afdeling Revalidatie; 2016.

21.

Kalf H, de Swart BJM, Bonnier-Baars M, Kanters J, Hofman M, Kocken J, et al. Logopedie bij de ziekte van Parkinsons: een richtlijn van de Nederlandse Vereniging voor Logopedie en Foniatrie. Woerden: Nederlandse Vereniging voor Logopedie en Foniatrie; 2008.

22.

Bloem BR, Rompen L, Vries NM, Klink A, Munneke M, Jeurissen P. ParkinsonNet: a low-cost health care innovation with a systems approach from The Netherlands. Health Aff (Millwood). 2017;36(11):1987–96. https://doi.org/10.1377/hlthaff.2017.0832.CrossRef

23.

Bloem BR, Munneke M. Revolutionising management of chronic disease: the ParkinsonNet approach. BMJ. 2014;348:g1838.CrossRef

24.

BV C. Castor Electronic Data Capture. Amsterdam. 2016.

25.

Postuma RB, Berg D, Stern M, Poewe W, Olanow CW, Oertel W, et al. MDS clinical diagnostic criteria for Parkinson’s disease. Mov Disord. 2015;30(12):1591–601. https://doi.org/10.1002/mds.26424.CrossRefPubMed

26.

Kalf JG, De Swart BJM, Bonnier-Baars M, Hofman M, Kanters J, Kocken J, et al. Guidelines for speech-language therapy in Parkinson’s disease. Nijmegen, The Netherlands/Miami (FL), U.S.A.: Lemma Publishers; 2011.

27.

Sturkenboom IH, Graff MJ, Borm GF, Veenhuizen Y, Bloem BR, Munneke M, et al. The impact of occupational therapy in Parkinson’s disease: a randomized controlled feasibility study. Clin Rehabil. 2013;27(2):99–112. https://doi.org/10.1177/0269215512448382.CrossRefPubMed

28.

Sturkenboom IHWM, Graff MJL, Hendriks JCM, Veenhuizen Y, Munneke M, Bloem BR, et al. Efficacy of occupational therapy for patients with Parkinson’s disease: a randomised controlled trial. Lancet Neurol. 2014;13(6):557–66. https://doi.org/10.1016/S1474-4422(14)70055-9.CrossRefPubMed

29.

Ginis P, Nackaerts E, Nieuwboer A, Heremans E. Cueing for people with Parkinson’s disease with freezing of gait: a narrative review of the state-of-the-art and novel perspectives. Ann Phys Rehabil Med. 2017;61(6):407–13. https://doi.org/10.1016/j.rehab.2017.08.002.CrossRefPubMed

30.

De Monchy N. Een app ter ondersteuning van logopedische behandeling. Parkinson Magazine. 2015;1:14–5.

31.

Kalf H, van Zundert S, Scholten S, van Dongen-Stiemer F, Donkers A, Wassenaar-Dam C, et al. Logopedie bij de ziekte van Parkinson, een herziene richtlijn van de Nederlandse Vereniging voor Logopedie en Foniatrie. Woerden: Nederlandse Vereniging voor Logopedie en Foniatrie; 2017.

32.

Jenkinson C, Fitzpatrick R, Peto V, Greenhall R, Hyman N. The Parkinson’s Disease Questionnaire (PDQ-39): development and validation of a Parkinson’s disease summary index score. Age Ageing. 1997;26(5):353–7. https://doi.org/10.1093/ageing/26.5.353.CrossRefPubMed

33.

Peto V, Jenkinson C, Fitzpatrick R. Determining minimally important differences for the PDQ-39 Parkinson’s disease questionnaire. Age Ageing. 2001;30(4):299–302. https://doi.org/10.1093/ageing/30.4.299.CrossRefPubMed

34.

Peto V, Jenkinson C, Fitzpatrick R, Greenhall R. The development and validation of a short measure of functioning and well being for individuals with Parkinson’s disease. Qual Life Res. 1995;4(3):241–8.CrossRef

35.

Chen K, Yang YJ, Liu FT, Li DK, Bu LL, Yang K, et al. Evaluation of PDQ-8 and its relationship with PDQ-39 in China: a three-year longitudinal study. Health Qual Life Outcomes. 2017;15(1):170. https://doi.org/10.1186/s12955-017-0742-5.CrossRefPubMedPubMedCentral

36.

Folstein MF, Folstein SE, McHugh PR. “Mini-mental state”: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12(3):189–98. https://doi.org/10.1016/0022-3956(75)90026-6.CrossRefPubMed

37.

Mirandez RM, Aprahamian I, Talib LL, Forlenza OV, Radanovic M. Multiple category verbal fluency in mild cognitive impairment and correlation with CSF biomarkers for Alzheimer’s disease. Int Psychogeriatr. 2017;29(6):949–58. https://doi.org/10.1017/S1041610217000102.CrossRefPubMed

38.

Hoehn MM, Yahr MD. Parkinsonism. onset, progression, and mortality. 1967;17(5):427.

39.

Goetz CG, Tilley BC, Shaftman SR, Stebbins GT, Fahn S, Martinez-Martin P, et al. Movement Disorder Society-sponsored revision of the Unified Parkinson’s Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord. 2008;23(15):2129–70.CrossRef

40.

Balestroni G, Bertolotti G. EuroQol-5D (EQ-5D): an instrument for measuring quality of life. Monaldi Arch Chest Dis. 2012;78(3):155–9.PubMed

41.

Knuijt S, Kalf JG, van Engelen BGM, de Swart BJM, Geurts ACH. The Radboud Dysarthria Assessment: development and clinimetric evaluation. Folia Phoniatr Logop. 2017;69(4):143–53.CrossRef

42.

Maryn Y, De Bodt M, Roy N. The Acoustic Voice Quality Index: toward improved treatment outcomes assessment in voice disorders. J Commun Disord. 2010;43(3):161–74. https://doi.org/10.1016/j.jcomdis.2009.12.004.CrossRefPubMed

43.

Jacobson BH, Johnson A, Grywalski C, Silbergleit A, Jacobson G, Benninger MS, et al. The Voice Handicap Index (VHI). Am J Speech Lang Pathol. 1997;6(3):66–70. https://doi.org/10.1044/1058-0360.0603.66.CrossRef

44.

Kalf JG, Borm GF, de Swart BJ, Bloem BR, Zwarts MJ, Munneke M. Reproducibility and validity of patient-rated assessment of speech, swallowing, and saliva control in Parkinson’s disease. Arch Phys Med Rehabil. 2011;92(7):1152–8. https://doi.org/10.1016/j.apmr.2011.02.011.CrossRefPubMed

45.

Martens H, Nuffelen G, Bodt M. Nederlandstalig Spraakverstaanbaarheidsonderzoek - Zinsniveau (NSVO-Z). In: Dutch Sentence Intelligibility Assessment (DSIA); 2010.

46.

Higginson IJ, Gao W, Jackson D, Murray J, Harding R. Short-form Zarit Caregiver Burden Interviews were valid in advanced conditions. J Clin Epidemiol. 2010;63(5):535–42. https://doi.org/10.1016/j.jclinepi.2009.06.014.CrossRefPubMed

47.

Herrmann C. International experiences with the Hospital Anxiety and Depression Scale-a review of validation data and clinical results. J Psychosom Res. 1997;42(1):17–41. https://doi.org/10.1016/S0022-3999(96)00216-4.CrossRefPubMed

48.

Kanna SV, Bhanu K. A simple bedside test to assess the swallowing dysfunction in Parkinson’s disease. Ann Indian Acad Neurol. 2014;17(1):62–5. https://doi.org/10.4103/0972-2327.128556.CrossRefPubMedPubMedCentral

49.

El Sharkawi A, Ramig L, Logemann JA, Pauloski BR, Rademaker AW, Smith CH, et al. Swallowing and voice effects of Lee Silverman Voice Treatment (LSVT): a pilot study. J Neurol Neurosurg Psychiatry. 2002;72(1):31–6. https://doi.org/10.1136/jnnp.72.1.31.CrossRefPubMedPubMedCentral

50.

Marck MA, Bloem BR, Borm GF, Overeem S, Munneke M, Guttman M. Effectiveness of multidisciplinary care for Parkinson’s disease: a randomized, controlled trial. Mov Disord. 2013;28(5):605–11. https://doi.org/10.1002/mds.25194.CrossRefPubMed

51.

J. Holmes R, M. Oates J, J. Phyland D, J. Hughes A. Voice characteristics in the progression of Parkinson’s disease. Int J Lang Commun Disord. 2000;35(3):407–18. https://doi.org/10.1080/136828200410654.CrossRef

Title: Design of the PERSPECTIVE study: PERsonalized SPEeCh Therapy for actIVE conversation in Parkinson’s disease (randomized controlled trial)
Authors: J. J. L. Maas
N. M. De Vries
B. R. Bloem
J. G. Kalf
Publication date: 01-12-2022
Publisher: BioMed Central
Keyword: Parkinson's Disease
Published in: Trials / Issue 1/2022
Electronic ISSN: 1745-6215
DOI: https://doi.org/10.1186/s13063-022-06160-9

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Design of the PERSPECTIVE study: PERsonalized SPEeCh Therapy for actIVE conversation in Parkinson’s disease (randomized controlled trial)

Abstract

Objective

Background

Methods

Results

Conclusions

Trial registration

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Objective

Background

Methods

Results

Conclusions

Trial registration

Please log in to get access to this content

Other articles of this Issue 1/2022

Effect of early stellate ganglion block in cerebral vasospasm after aneurysmal subarachnoid hemorrhage (BLOCK-CVS): study protocol for a randomized controlled trial

A randomized non-inferiority study of low-dose and standard-dose ticagrelor after intervention for acute coronary syndrome: study protocol for the TIGER STUDY

An online behavior change intervention to promote physical activity in adults with asthma: study protocol for a multicenter randomized controlled trial

Effectiveness of intensive perioperative nutrition therapy among adults undergoing gastrointestinal and oncological surgery in a public hospital: study protocol for a pragmatic randomized control trial

The INVENT COVID trial: a structured protocol for a randomized controlled trial investigating the efficacy and safety of intravenous imatinib mesylate (Impentri®) in subjects with acute respiratory distress syndrome induced by COVID-19

Evaluation of the safety and efficacy of a Fuling-Zexie decoction for people with asymptomatic hyperuricemia: protocol for a prospective, double-blinded, randomized, placebo-controlled clinical trial